| Filed On | Filing |
|---|---|
| 16 Nov 2026 | D |
| 12 Nov 2026 | 425 |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | S-8 |
| 12 Nov 2026 | S-8 POS |
| 12 Nov 2026 | S-8 POS |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Zelsuvmi® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025 |
| 03 Nov 2026 | SCHEDULE 13D/A |
| 30 Oct 2026 | 425 |
| 30 Oct 2026 | 425 |
| 30 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +6 more
Form of Amended and Restated Limited Liability Company Agreement of the Surviving Company |
| 06 Oct 2026 |
Form 4: Greenleaf Peter, Director
Sold 797 shares ($16.9K) |
| 06 Oct 2026 |
Form 4: Friedberg Ezra M, Director
Sold 558 shares ($11.6K) |
| 06 Oct 2026 |
Form 4: Pauls Matthew, Director
Sold 786 shares ($16.5K) |
| 01 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) The purpose of this 2026 Equity Incentive Plan (the “Plan”) is to encourage key service providers of Pelthos Therapeutics Inc. (the “Company”) and its Subsidiaries (as defined below) to continue their association with the Company by ... |
| 18 Aug 2026 | ARS |
| 18 Aug 2026 | DEFA14A |
| 18 Aug 2026 | Proxy statement: annual meeting on September 29, 2026 |
| 13 Aug 2026 | 10-Q |
Loading...